



PET/CT Referral Form

6 Tsienneto Road, Suite 100LL, Derry, NH 03038
Scheduling: 603.537.1363 | Fax: 603.537.1324

PATIENT INFORMATION

<input type="checkbox"/> Patient Name	<input type="checkbox"/> Date of Birth	<input type="checkbox"/> Height	<input type="checkbox"/> Weight
<input type="checkbox"/> Patient Address	<input type="checkbox"/> Patient Telephone #	<input type="checkbox"/> Patient Mobile #	
<input type="checkbox"/> Referring Provider	<input type="checkbox"/> Provider Telephone #	<input type="checkbox"/> Provider Fax#	

^[12] SIGNS AND SYMPTOMS (REQUIRED)

Histologically Proven Suspected

Type of cancer _____

Please check Radiopharmaceutical

FDG

CPT Codes _____

If provided a specific CPT code, please provide.

NETSPOT

AXUMIN

INSURANCE INFORMATION

Primary Insurance _____ Subscribers Insurance ID # _____

Secondary Insurance _____ Insurance Prior Authorization # _____

CMS/APPROPRIATE USE CRITERIA (FOR MEDICARE PART B PATIENTS ONLY)

NPI# _____ **Name of CDSM Consulted (software used)** _____ **Determination Result (check one):**

1) Adheres to 2) Does Not Adhere to 3) Not Applicable

^[15] (Check ONE and fill out corresponding section completely)

Initial Treatment Strategy

Diagnosis: Abnormal finding of _____
Based on _____

Check one

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent,

Initial Staging: of confirmed newly diagnosed cancer

Check one

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent.

Other (e.g., Alzheimer's Disease). Please list reason for scan here: _____

Subsequent Treatment Strategy

Restaging: (after the completion of treatment)

Check one

Status post the completion of treatment for the purpose of detecting residual disease
Last date of treatment: _____
Type of treatment: _____

Detecting suspected recurrence, or metastasis of previously treated cancer:
Site of suspected recurrence / metastasis: _____
Based on: _____

Determine the extent of a known recurrence.
Confirmed by: _____

PET/CT is being used to potentially replace one or more imaging studies that (1) is being utilized to determine extent of known recurrence of (2) provided insufficient information for the clinical management of the patient.

Monitoring Tumor Response: During Treatment

Check one

Chemotherapy Radiotherapy Other (specify): _____

^[16] PRESCREENING QUESTIONNAIRE

Pregnant: <input type="checkbox"/> Y <input type="checkbox"/> N	Prior Studies/Treatment	Previous: <input type="checkbox"/> CT <input type="checkbox"/> MRI <input type="checkbox"/> PET/CT	Where: _____	When: _____
Diabetes: <input type="checkbox"/> Y <input type="checkbox"/> N		Pathology: <input type="checkbox"/> Y <input type="checkbox"/> N	Where: _____	When: _____
		Radiation Therapy: <input type="checkbox"/> Y <input type="checkbox"/> N	Provider: _____	When: _____
		Chemotherapy: <input type="checkbox"/> Y <input type="checkbox"/> N	Provider: _____	When: _____

Authorized Treating Provider's Signature: (Stamps Not Accepted) _____ **NPI #** _____ **Date** _____

Services provided by

Please FAX this form (and recent office notes, radiology reports and pathology reports) to Scheduling Department after patient's examination has been scheduled.